About DSANJ

What is DSANJ?

The Drug Seeds Alliance Network Japan (DSANJ) is a program aimed at promoting drug discovery research in Japan by matching the drug discovery seeds and platform technologies achieved by universities, research institutes, and startups in Japan and worldwide with pharma companies and venture capital(VC) with the aim of sparking developing new drugs.

DSANJ Bio Conference at a Glance

Part of the program is the DSANJ Bio Conference, which matches researchers and startups with promising new drug discovery seeds and platform technologies with pharma companies and VC.

DSANJ Bio Conference 2025: Overview

Purpose Promoting joint research, technology transfer and investment in drug discovery
Program One-on-one meetings (held online) between researchers, startups, etc., and pharma companies and VC
Schedule Mid-2025: 10:00–18:00 (JST) on Aug. 27, 28, 29; Sep. 1, 2
Early 2026: 10:00–18:00 (JST) on Jan. 28, 29, 30; Feb. 2, 3
Participants
  • Researchers, startups, etc., with promising new drug discovery seeds and platform technologies
  • Pharma companies and VC
Area of focus

  • Categories

    Drug targets; drug seeds (substances); platform technologies for drug discovery; biomarkers; diagnostic drugs and technologies; digital therapeutics; medical devices for use combination with drugs, etc. (i.e., excluding devices designed for use on their own)

  • Modalities

    Low-molecular drugs, antibody drugs, oligonucleotide therapeutics, gene therapy, recombinant protein, cell therapy, AI-powered drug discovery, vaccines, viruses, regenerative medicine, SaMD (treatment apps), digital healthcare, protein-protein interaction inhibitors, etc.

  • Target Disorders

    Metabolic disorders, circulatory disorders, infectious disorders, respiratory disorders, musculoskeletal disorders, cancer and malignant neoplasms, central nervous system disorders, pain, sensory organ disorders, immune system and inflammatory disorders, allergies, skin disorders, digestive and urinary disorders, ob-gyn disorders, rare disorders, etc.

  • Stage of Research Progress

    Basic research; non-clinical POC pending; non-clinical POC obtained, clinical trials pending; clinical trials underway, etc.
Organizers OCCI, Japan Agency for Medical Research and Development (AMED), Japan Pharmaceutical Manufacturers Association, Kansai Pharmaceutical Industries Association
Co-organizer Osaka Prefecture
Support Japan External Trade Organization (JETRO), Osaka City
Special thanks Life Science Innovation Network Japan (LINK-J)

DSANJ Bio Conference (2010–2024): By the Numbers

  • Total 1,900 proposals have submitted
  • Total meetings resulting from conference: 9,333 (avg. 4.9 meetings requested per proposal)
  • Total 492 pharma companies have participated (39 in 2024)
  • Total 308 research institutions and startups have participated from throughout Japan and around the world

Joint Research Deals Reached (2010–2024)

  • Total 1,900 proposals have submitted, and resulted in 78 joint research deals reached (as of Feb. 2024)
DSANJ Bio Conference (2010–2024): By the Numbers

DSANJ Networks: Japanese & Global

We have partnered with 262 universities, research institutions, startups, etc., throughout Japan
We have partnered with 104 institutions in 25 countries